Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016310 | 1.00 | HRH4 (0.38) | HRH4HRH3KDM4EPOLB | |
| SCHEMBL24770440 | 1.00 | HRH4 (0.38) | HRH4HRH3KDM4EPOLB | |
| SCHEMBL24910867 | 0.91 | HRH4 (0.33) | HRH4HRH3KDM4EPOLB | |
| SCHEMBL19684411 | 0.82 | — | — | |
| SCHEMBL22271619 | 0.81 | EPHX1 (0.41) | — | |
| SCHEMBL23943203 | 0.79 | CYP2C19 (0.46) | HRH4HRH3 | |
| SCHEMBL21534373 | 0.78 | ADRA1A (0.34) | KDM4E | |
| SCHEMBL19451247 | 0.78 | POLB (0.34) | HRH4HRH3POLB | |
| SCHEMBL1276622 | 0.76 | HRH4 (0.45) | HRH4HRH3KDM4EPOLB | |
| SCHEMBL14176497 | 0.76 | HRH4 (0.45) | HRH4HRH3KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | HRH4 717/4885HRH3 527/4885KDM4E 4593/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | HRH4 717/4885HRH3 527/4885KDM4E 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.